National Hospital of Ophthalmology of Quinze-Vingts

What National Hospital of Ophthalmology of Quinze-Vingts does

The National Hospital of Ophthalmology of Quinze-Vingts (Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts), founded in 1260 by King Saint Louis and located at 28 rue de Charenton in Paris, is the French national reference hospital for ophthalmology. It delivers the full spectrum of eye care through specialized centers covering consultations, retina, cornea, glaucoma, refractive surgery, strabismus, infectious ocular pathologies, and a 24/7 ophthalmological emergency service. The hospital serves as coordinating center for the RefeRet rare neuro-retinal disease network and runs a high-volume ambulatory surgery program (90.2% ambulatory rate in 2025) supported by 9 operating rooms including ISO 5 facilities. It is the first French institution to administer Luxturna gene therapy (28 patients since 2018) and is currently the sole European site for the ANSM-approved REVISE gene therapy trial for Leber Hereditary Optic Neuropathy.

Revenue is generated through reimbursement from the French national health insurance system (Sécurité Sociale) for consultations, hospitalizations, surgeries, and emergency services, with pricing regulated by the national fee schedule and EU patients covered via the European Health Insurance Card. The hospital monetizes its clinical research capacity through partnerships with pharmaceutical companies (Novartis, GenSight Biologics) and translational research collaborations, and operates a non-profit foundation (Fondation 15-20 pour la vision) for donations. It is structurally integrated with the Institut de la Vision and the IHU FOReSIGHT research institute on the same campus, and in 2025 launched the first Health Data Warehouse entirely dedicated to ophthalmology, creating a substrate for data-intensive research and precision medicine partnerships.

Name

National Hospital of Ophthalmology of Quinze-Vingts

Legal name

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts

Website

https://15-20.fr

Company type

Private

Operating status

Operating

Headcount range

501–1,000 employees

Short description

The National Hospital of Ophthalmology of Quinze-Vingts is a Paris-based French national reference public hospital founded in 1260, providing comprehensive ophthalmological care across all eye conditions, rare retinal diseases, and gene therapy, serving general, emergency, and international patients reimbursed through the French national health insurance system.

Ownership category

akta.pro rank

Product category

Ophthalmology Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Offices of Physicians (6211), Offices of Physicians (62111)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Hospitals (8060), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Ophthalmic Specialty Hospitals (HLAFAHAJ)

akta.pro secondary industries

Ophthalmology Surgery Centers (HLAFAIAF), Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN), Retina & Vitreous Specialists (HLAKAKAE)

Keywords

• Ophthalmology services
• Eye surgery
• Rare eye diseases
• Retinal treatment
• Visual rehabilitation

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. Public Healthcare Reimbursement: As a French public hospital, revenue is generated through the national health insurance system (Sécurité Sociale) reimbursing medical procedures, consultations, hospitalizations, and surgeries performed on patients.

Pricing tiers

Go-to-market motion3 records

Distribution channels8 records

Marketing channels7 records

Core offering

The National Hospital of Ophthalmology of Quinze-Vingts is a French public hospital providing comprehensive ophthalmological care, including specialized consultations (retina, cornea, glaucoma, refractive surgery), 24/7 emergency services, ambulatory and inpatient surgery, rare eye disease reference center coordination, and access to innovative therapies including gene therapy (Luxturna). The hospital also operates a Clinical Investigation Center, the IHU FOReSIGHT research institute, and the Institut Saint-Louis for visual rehabilitation.

Product overview

The National Hospital of Ophthalmology of Quinze-Vingts (Hôpital National des Quinze-Vingts) is a French public hospital providing comprehensive ophthalmological care. Its service portfolio encompasses specialized consultation centers (eye consultations, retina center, cornea center, glaucoma institute), rare disease reference centers (RefeRet for neuro-retinal diseases), emergency services (24/7 ophthalmological emergencies), and surgical services (ambulatory surgery with 90.2% day-surgery rate). The hospital integrates research through the IHU FOReSIGHT vision institute and Clinical Investigation Center, offering access to clinical trials including gene therapies like Luxturna. Patient education is supported through therapeutic workshops and the 'Au fond des yeux' podcast. The hospital operates in partnership with the Institut de la Vision for research activities.

Differentiator

Problem solved

Functional benefit

Products and services

• Centre des consultations d'ophtalmologie (Eye Consultations Center)
• Centre de la rétine (Retina Center)
• Institut universitaire du glaucome (University Glaucoma Institute)
• Centre de référence des maladies rares RefeRet (Rare Diseases Reference Center)
• Ambulatory Surgery Service (Chirurgie ambulatoire)
• Urgences ophtalmologiques (Ophthalmological Emergencies)
• Luxturna Gene Therapy Treatment
• Institut Saint-Louis (Saint-Louis Institute)
• Institut Hospitalo-Universitaire FOReSIGHT (IHU FOReSIGHT)
• Centre d'Investigation Clinique (Clinical Investigation Center)

Quantifiable outcome

• 90.2% of surgical activity performed as ambulatory surgery
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• GenSight BiologicscoreStrategic or Co-development Partner · 9 February 2026Clinical partnership for GS010/LUMEVOQ gene therapy for Leber Hereditary Optic Neuropathy (LHON). The 15-20 National Hospital is currently the only institution in Europe conducting a clinical study involving GS010, treating first patient in REVISE dose-ranging study approved by ANSM in December 2025.
• Institut CuriecoreStrategic or Co-development Partner · 1 January 2026Partnership to create CETO (Centre d'Expertise en Toxicité Oculaire - Center of Expertise in Ocular Toxicity), the first center in France dedicated to ocular toxicities from anticancer treatments. Combines expertise from both institutions.
• Institut Fyodorov (Moscow, Russia)coreStrategic or Co-development Partner · 1 January 2018Partnership agreement with the Fyodorov Institute including conference programs and exchange of expertise in ophthalmology. Pr Boris Malyugin from Fyodorov Institute delivered lectures at the 15-20 hospital.
• Institut de la VisioncoreStrategic or Co-development PartnerClose collaborative relationship with the Vision Institute located on the hospital campus, combining clinical care with fundamental and translational research in vision science.
• Better WorldcoreTechnology or IntegrationPartnership using artificial intelligence to analyze patient and professional expressions for quality improvement. Supported by the European Union and BPI (Banque Publique d'Investissement), making 15-20 the first public hospital to experiment with such AI for patient care.
• CHU de Bordeaux, CHU de Poitiers, CHU de Rennes, CHR d'Orléans, Hôpital Sainte-MariecoreStrategic or Co-development PartnerCompetence centers affiliated with the RefeRet rare disease reference center network, expanding access to specialized rare eye disease care across France.
• Filière SensgenecoreStrategic or Co-development PartnerThe RefeRet rare disease center is a member of the Sensgene health network for rare sensory diseases, coordinating care and research across the network.
• Studio OHzminorGTM or Marketing PartnerPodcast production partnership for the 'Au fond des yeux' podcast series, produced in collaboration with Institut de la Vision and IHU FOReSIGHT.
• IHU FOReSIGHTcoreStrategic or Co-development PartnerHospital-University Institute dedicated to vision research, led by Pr Christophe Baudouin. Hosted within the hospital, driving innovation in ophthalmology through translational research and the Surgery School.
• Association Française de la Relation Client (AFRC)minorOthersProfessional association that awarded the hospital the Silver Palm prize for patient experience excellence.
• NovartiscoreStrategic or Co-development PartnerPharmaceutical partnership for clinical trials and research in retinal diseases including the Prodigy study on cone protection in retinitis pigmentosa.

Scale indicators8 records

Recent moves14 records

Expansion highlights6 records

Regional players

• Singapore National Eye Centre (SNEC): Singapore's national specialty eye hospital and a regional referral hub for Southeast Asia. Comparable as a public specialty ophthalmology hospital combining high-volume surgery, research, and international patient flows, but operating in a different geography.
• CHNO des Quinze-Vingts Patient Service Competitors — CHU Nantes Ophthalmology: Constitutive member of Quinze-Vingts' RefeRet rare-disease network. Comparable as a French public academic ophthalmology department handling tertiary referrals, though embedded in a general university hospital rather than standalone specialty.

Direct peers

• Bascom Palmer Eye Institute: University of Miami specialty eye hospital, repeatedly ranked #1 in US ophthalmology. Comparable as a clinically dominant ophthalmology specialty hospital combining tertiary care, clinical research, and trials.
• Jules Gonin Eye Hospital (Hôpital ophtalmique Jules Gonin): Swiss university eye hospital in Lausanne, internationally renowned for retinal diseases and rare ocular conditions. Closely comparable as a European specialty ophthalmology hospital with strong clinical research and rare-disease expertise.
• Fondation Ophtalmologique Adolphe de Rothschild: Paris-based private non-profit ophthalmology hospital. A constitutive center of Quinze-Vingts' RefeRet network and the most direct French competitor in tertiary eye care, sharing rare-disease, surgical, and emergency offerings in the same city.
• Wills Eye Hospital: US specialty eye hospital consistently ranked among the top ophthalmology centers. Directly comparable as a high-volume, multi-specialty ophthalmology hospital with strong surgical outcomes, research programs, and 24/7 ophthalmic emergency services.
• Moorfields Eye Hospital NHS Foundation Trust: UK's flagship standalone ophthalmology hospital, founded in 1805. Comparable to Quinze-Vingts as a single-specialty eye hospital that combines routine ophthalmic surgery with a national/international referral role for rare eye disease, research, and clinical trials.
• Royal Victorian Eye and Ear Hospital: Australia's leading standalone eye and ear hospital, also a public specialty center. Comparable in scope and model — combining high-volume ophthalmology surgery, emergency services, and research/teaching.

Broad incumbents

• Massachusetts Eye and Ear: Harvard-affiliated specialty hospital for ophthalmology and otolaryngology. Comparable as a specialty teaching hospital with research-intensive ophthalmology practice, though broader in scope than Quinze-Vingts (also covers ENT).

Others

• Institut de la Vision (Sorbonne / INSERM): Vision research institute physically co-located with Quinze-Vingts. Not a competitor but a strategic research partner, jointly developing translational ophthalmology science with shared faculty and clinical pipelines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Quinze_Vingts
• YouTubeyoutube.com/channel/UCWnYbi1UTjx4QWvLyhRSSDA
• Facebookfacebook.com/Hopitaldes1520
• LinkedInlinkedin.com/company/centre-hospitalier-national-dophtalmologie-des-quinze-vingts
• Instagraminstagram.com/quinzevingts

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National Hospital of Ophthalmology of Quinze-Vingts